ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM
ImmunityBio, Inc. is receiving a Strong Buy rating due to promising clinical data for its product ANKTIVA. The drug's unique IL-15 mechanism has shown strong efficacy in treating solid tumors, particularly in patients with lymphopenia. With significant regulatory catalysts on the horizon, the company is poised to expand its market presence beyond bladder cancer.
- ▪ImmunityBio, Inc. has been rated as a Strong Buy based on its clinical data for ANKTIVA.
- ▪ANKTIVA's IL-15 mechanism enhances lymphocyte proliferation and shows strong efficacy in solid tumors.
- ▪The company is looking to expand its market opportunities beyond bladder cancer.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906453-immunitybio-looking-beyond-bladder-cancer-to-a-multibillion-dollar-solid-tumor-tam"},"author":{"@type":"Person","name":"Emanuel…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
